Bajaj Healthcare
NSE: BAJAJHCARE · Pharmaceuticals
Snapshot
Unlock Bajaj Healthcare's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Bajaj Healthcare Limited is a pharmaceutical company that develops, manufactures, and supplies a diverse range of active pharmaceutical ingredients (APIs), amino acids, and nutritional supplements. The company serves the pharmaceutical, nutraceutical, and food industries through both domestic and international markets.
Business Model
The company generates revenue by manufacturing and selling a broad portfolio of APIs and finished formulations, including tablets, capsules, and powders. It operates as both a domestic supplier and an exporter to global pharmaceutical and nutraceutical markets.
- Incorporation Year:1993
Growth Outlook
Growth is driven by the expansion of its extensive therapeutic product portfolio and the scaling of its manufacturing capabilities for APIs and nutritional supplements. The company continues to leverage its export network to capture demand in international pharmaceutical markets.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent international and domestic pharmaceutical quality standards and potential audits by health authorities.
- Raw Material Price Volatility. Fluctuations in the cost of chemical intermediates and raw materials can significantly impact the company's operating margins.
- Foreign Exchange Risk. As an exporter, the company is exposed to currency fluctuations that may affect the profitability of its international sales.
- Competitive Intensity. The pharmaceutical and API manufacturing sector is highly competitive, potentially leading to pricing pressures on generic products.
Price
Start your research today
Unlock AI insights, financials, peers and live data on Bajaj Healthcare and 5,000+ companies — free.
Key Metrics
REVENUE
₹611 Cr
TTM · standalone
NET PROFIT
₹16 Cr
TTM · standalone
EPS
₹6.82
TTM · standalone
RETURN ON EQUITY
3.3%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
9.0%
TTM · standalone
P/E
54.7x
Q4 FY26 · standalone
EV/EBITDA
13.0x
Q4 FY26 · standalone
EBITDA MARGIN
18.3%
TTM · standalone
NET PROFIT MARGIN
-14.9%
Q4 FY26 · standalone
DEBT TO EQUITY
0.4x
Q4 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Bajaj HealthcareBAJAJHCARE | 1,040 | 54.68 | 12.96 | 12.6% | 18.3% | 3.3% | 9.0% | -28.9% |
Sakar HealthcareSAKAR | 1,148 | 65.52 | 28.44 | 41.8% | 28.3% | 10.3% | 13.3% | +148.6% |
Beta Drugs LtdBETA | 1,096 | — | — | — | 20.0% | — | — | +34.8% |
Kilitch DrugsKILITCH | 1,091 | 13.45 | 14.88 | 18.7% | 20.3% | 13.3% | 17.3% | -60.2% |
Syncom Formul.SYNCOMF | 1,082 | 15.39 | 11.81 | 5.0% | 22.2% | 21.2% | 27.4% | -27.3% |
Fermenta Biotec.FERMENTA | 1,000 | 18.39 | 11.42 | 11.9% | 23.3% | 19.0% | 26.1% | +21.4% |
As of Q4 FY26
Financials
Bajaj Healthcare
NSE: BAJAJHCARE · Pharmaceuticals
Snapshot
Unlock Bajaj Healthcare's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Bajaj Healthcare Limited is a pharmaceutical company that develops, manufactures, and supplies a diverse range of active pharmaceutical ingredients (APIs), amino acids, and nutritional supplements. The company serves the pharmaceutical, nutraceutical, and food industries through both domestic and international markets.
Business Model
The company generates revenue by manufacturing and selling a broad portfolio of APIs and finished formulations, including tablets, capsules, and powders. It operates as both a domestic supplier and an exporter to global pharmaceutical and nutraceutical markets.
- Incorporation Year:1993
Growth Outlook
Growth is driven by the expansion of its extensive therapeutic product portfolio and the scaling of its manufacturing capabilities for APIs and nutritional supplements. The company continues to leverage its export network to capture demand in international pharmaceutical markets.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent international and domestic pharmaceutical quality standards and potential audits by health authorities.
- Raw Material Price Volatility. Fluctuations in the cost of chemical intermediates and raw materials can significantly impact the company's operating margins.
- Foreign Exchange Risk. As an exporter, the company is exposed to currency fluctuations that may affect the profitability of its international sales.
- Competitive Intensity. The pharmaceutical and API manufacturing sector is highly competitive, potentially leading to pricing pressures on generic products.
Price
Loading…
Start your research today
Unlock AI insights, financials, peers and live data on Bajaj Healthcare and 5,000+ companies — free.
Key Metrics
REVENUE
₹611 Cr
TTM · standalone
NET PROFIT
₹16 Cr
TTM · standalone
EPS
₹6.82
TTM · standalone
RETURN ON EQUITY
3.3%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
9.0%
TTM · standalone
P/E
54.7x
Q4 FY26 · standalone
EV/EBITDA
13.0x
Q4 FY26 · standalone
EBITDA MARGIN
18.3%
TTM · standalone
NET PROFIT MARGIN
-14.9%
Q4 FY26 · standalone
DEBT TO EQUITY
0.4x
Q4 FY26 · standalone
Peers · Pharmaceuticals
As of Q4 FY26